Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".
Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".